Generic Drug Industry Market Research & Statistics

Global Generic Drug Industry

 

The global generic drug market should grow at a compound annual growth rate of 15% over five years to be worth just under $169 billion in 2014, according to a report from BCC Research.

 

The generic drug industry covers the marketing and sale of medication containing the same active ingredients and dosages as brand-name drugs manufactured by the pharmaceutical industry. Drugs can be prescribed under their chemical name without specifying a particular pharmaceutical brand or company. A key benefit of generic drugs is that they usually cost a fraction of the price of brand-name drugs, as much as 80% to 85% less according to the US Food and Drug Administration. For example, Glucotrol, a drug used in the treatment of diabetes, represents a monthly cost to patients of between $42 and $84 for 10 mg tablets; however, the drug’s generic version, Glipizide, costs up to 10 times less at between $4 and $8 per month.

 

Generic drugs are under the same governance as brand-name drugs and must adhere to the same standards. When brand-name drugs come off patent, the market is opened up to generic versions. Patent protection generally protects a drug’s intellectual property rights for about 20 years, but as the patent is effective from the clinical trial stage, the actual time the drug is on the market can be far less, often between 10 and 14 years. After a patent expires, pharmaceutical companies come under fierce pricing pressure due to competition from their less-expensive generic counterparts.

 

Drugs coming off patent through 2014 represent a forecast annual loss of $136 billion, according to industry analysis. Generics help reduce government spending on healthcare, accounting in part for a near 5% decrease in US drug spending, reports the FDA. The FDA acts as a governing body for generic drugs to enforce maximum standards of variation with brand-name drugs. However, in an 11-year study, variation in absorption of branded and generic drugs was found to be as little as 3.5%. Such negligible variation could equally exist in a comparison of two branded drugs.

 

Value of Products at risk to Generic Competition - 2010 to 2014 

 


More »
24/7 Customer Support

Talk to Sam

+1 718 473 0872

You might be interested in: generics, biosimilars, drug, more »

1-10 of about 200 reports

Download Unlimited Documents from Trusted Public Sources

Generic Drug Spending in the US - Forecast

  • Fda's Proposed Generic Drug Labeling Rule: an Economic Assessmen...
  • February 2014
    15 pages
  • Generic Drug  

    Pharmaceutical  

  • United States  

View report >

Generic Drugs Industry in Japan

  • Promotion of Use of Generic Drugs in Japan
  • July 2012
    15 pages
  • Generic Drugs  

  • Japan  

View report >

Generic Drugs Industry in Brazil

  • Generic Drug Business in Brazil
  • October 2012
    44 pages
  • Generic Drugs  

  • Brazil  

    World  

View report >

Generic Drug Industry in India and the US - Forecast

  • Trade-technology E-zine 44
  • November 2012
    5 pages
  • Generic Drug  

  • India  

    United States  

View report >

Generic Drug Industry in China

  • Leaching Patterns of Fipronil in 3 Kinds of Soil in Hainan Provi...
  • January 2013
    6 pages
  • Generic Drug  

  • China  

View report >

Biosimilars Market Forecast in Europe

  • After Generics It's the Turn of Biosimilars, a Budding Market
  • September 2014
    2 pages
  • Biosimilars  

    Drug  

  • Europe  

    Spain  

    World  

View report >

Generic Drug Statistics

  • Dr Reddy's Laboratories (drredd)
  • July 2014
    14 pages
  • Generic Drug  

  • India  

    United States  

    Russian Federat...  

View report >

Generics Markets in the US

  • July 2014
    12 pages
  • Generics  

  • United States  

View report >

Pathology Description in the US

  • Randomized Controlled Trial of Early Zoledronic Acid in Men with...
  • April 2014
    9 pages
  • Pathology  

    Generic Drug  

  • United States  

View report >

Drug Industry

  • Lessons for Follow-on Biologics from Small Molecule Drugs
  • February 2014
    16 pages
  • Drug  

View report >

Search in Generic Drug Industry (About 200 reports)

About 600 reports

Purchase Reports From Reputable Market Research Publishers
(From $ 63 - $ 9 300)

Adalimumab  - Comprehensive patent search

Adalimumab - Comprehensive patent search

  • $ 10 118
  • Company report
  • August 2014
  • by Ark Patent Intelligence

Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world's leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are ...

Amphotericin B - Comprehensive Patent Search

August 2014 $ 10 118

Bemiparin Sodium - Comprehensive Patent Search

August 2014 $ 10 118

Bevacizumab - Comprehensive Patent Search

August 2014 $ 10 118

Cefovecin (vet) - Comprehensive Patent Search

August 2014 $ 10 118

Cetuximab - Comprehensive Patent Search

August 2014 $ 10 118

Darbepoetin Alfa - Comprehensive Patent Search

August 2014 $ 10 118

Dexmedetomidine - Comprehensive Patent Search

August 2014 $ 10 118

Docetaxel - Comprehensive Patent Search

August 2014 $ 10 118

Efavirenz - Comprehensive Patent Search

August 2014 $ 10 118


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.